Health utilities lost and risk factors associated with HPV-induced diseases in men and women

The HPV Italian collaborative study group

Andrea Marcellusi, Alessandro Capone, Giampiero Favato, Francesco Saverio Mennini, Gianluca Baio, Katrin Haeussler, Marco Bononi, A. Crocetti, A. De Cesare, M. Miccini, P. Sapienza, M. C. Da Mosto, P. Boscolo-Rizzo, M. Stellin, R. Fuson, G. Palamara, M. Giuliani, M. Picardo, D. Panatto, T. Sasso & 8 others R. Gasparini, P. Cristoforoni, E. Di Capua, R. De Vincenzo, C. Ricci, C. Conte, G. Scambia, G. Ferrandina

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by ∼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P <0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.

Original languageEnglish
Pages (from-to)156-167
Number of pages12
JournalClinical Therapeutics
Volume37
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Warts
Cervical Intraepithelial Neoplasia
Health
Head and Neck Neoplasms
Quality of Life
Anus Neoplasms
Pathology
Italy
Papillomavirus Infections
Healthy Volunteers
Vaccination
Squamous Cell Neoplasms
Immunization Programs
Patient Preference
Sexual Partners
Human Development
Uterine Cervical Neoplasms
Sexual Behavior
Cost-Benefit Analysis
Colorectal Neoplasms

Keywords

  • Anal cancer
  • Anogenital warts
  • Cervical cancer
  • CIN 1
  • CIN 2-3
  • Head and neck squamous cell carcinoma
  • HPV
  • Quality of life
  • TTO
  • Utilities

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Health utilities lost and risk factors associated with HPV-induced diseases in men and women : The HPV Italian collaborative study group. / Marcellusi, Andrea; Capone, Alessandro; Favato, Giampiero; Mennini, Francesco Saverio; Baio, Gianluca; Haeussler, Katrin; Bononi, Marco; Crocetti, A.; De Cesare, A.; Miccini, M.; Sapienza, P.; Da Mosto, M. C.; Boscolo-Rizzo, P.; Stellin, M.; Fuson, R.; Palamara, G.; Giuliani, M.; Picardo, M.; Panatto, D.; Sasso, T.; Gasparini, R.; Cristoforoni, P.; Di Capua, E.; De Vincenzo, R.; Ricci, C.; Conte, C.; Scambia, G.; Ferrandina, G.

In: Clinical Therapeutics, Vol. 37, No. 1, 01.01.2015, p. 156-167.

Research output: Contribution to journalArticle

Marcellusi, A, Capone, A, Favato, G, Mennini, FS, Baio, G, Haeussler, K, Bononi, M, Crocetti, A, De Cesare, A, Miccini, M, Sapienza, P, Da Mosto, MC, Boscolo-Rizzo, P, Stellin, M, Fuson, R, Palamara, G, Giuliani, M, Picardo, M, Panatto, D, Sasso, T, Gasparini, R, Cristoforoni, P, Di Capua, E, De Vincenzo, R, Ricci, C, Conte, C, Scambia, G & Ferrandina, G 2015, 'Health utilities lost and risk factors associated with HPV-induced diseases in men and women: The HPV Italian collaborative study group', Clinical Therapeutics, vol. 37, no. 1, pp. 156-167. https://doi.org/10.1016/j.clinthera.2014.11.002
Marcellusi, Andrea ; Capone, Alessandro ; Favato, Giampiero ; Mennini, Francesco Saverio ; Baio, Gianluca ; Haeussler, Katrin ; Bononi, Marco ; Crocetti, A. ; De Cesare, A. ; Miccini, M. ; Sapienza, P. ; Da Mosto, M. C. ; Boscolo-Rizzo, P. ; Stellin, M. ; Fuson, R. ; Palamara, G. ; Giuliani, M. ; Picardo, M. ; Panatto, D. ; Sasso, T. ; Gasparini, R. ; Cristoforoni, P. ; Di Capua, E. ; De Vincenzo, R. ; Ricci, C. ; Conte, C. ; Scambia, G. ; Ferrandina, G. / Health utilities lost and risk factors associated with HPV-induced diseases in men and women : The HPV Italian collaborative study group. In: Clinical Therapeutics. 2015 ; Vol. 37, No. 1. pp. 156-167.
@article{a38b837565474c269c71e2fda88e3e03,
title = "Health utilities lost and risk factors associated with HPV-induced diseases in men and women: The HPV Italian collaborative study group",
abstract = "Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by ∼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P <0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.",
keywords = "Anal cancer, Anogenital warts, Cervical cancer, CIN 1, CIN 2-3, Head and neck squamous cell carcinoma, HPV, Quality of life, TTO, Utilities",
author = "Andrea Marcellusi and Alessandro Capone and Giampiero Favato and Mennini, {Francesco Saverio} and Gianluca Baio and Katrin Haeussler and Marco Bononi and A. Crocetti and {De Cesare}, A. and M. Miccini and P. Sapienza and {Da Mosto}, {M. C.} and P. Boscolo-Rizzo and M. Stellin and R. Fuson and G. Palamara and M. Giuliani and M. Picardo and D. Panatto and T. Sasso and R. Gasparini and P. Cristoforoni and {Di Capua}, E. and {De Vincenzo}, R. and C. Ricci and C. Conte and G. Scambia and G. Ferrandina",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.clinthera.2014.11.002",
language = "English",
volume = "37",
pages = "156--167",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica Inc.",
number = "1",

}

TY - JOUR

T1 - Health utilities lost and risk factors associated with HPV-induced diseases in men and women

T2 - The HPV Italian collaborative study group

AU - Marcellusi, Andrea

AU - Capone, Alessandro

AU - Favato, Giampiero

AU - Mennini, Francesco Saverio

AU - Baio, Gianluca

AU - Haeussler, Katrin

AU - Bononi, Marco

AU - Crocetti, A.

AU - De Cesare, A.

AU - Miccini, M.

AU - Sapienza, P.

AU - Da Mosto, M. C.

AU - Boscolo-Rizzo, P.

AU - Stellin, M.

AU - Fuson, R.

AU - Palamara, G.

AU - Giuliani, M.

AU - Picardo, M.

AU - Panatto, D.

AU - Sasso, T.

AU - Gasparini, R.

AU - Cristoforoni, P.

AU - Di Capua, E.

AU - De Vincenzo, R.

AU - Ricci, C.

AU - Conte, C.

AU - Scambia, G.

AU - Ferrandina, G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by ∼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P <0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.

AB - Purpose: A complete economic evaluation requires accurate data concerning the resources used, outcomes, and utilities (patient's preferences) to properly value the cost utility of human papillomavirus (HPV) vaccination strategies. This study was designed to measure the utility loss in health states affected by a broad range of HPV-induced pathologies in both sexes in Italy. As a secondary objective, risk factors influencing the viral transmission and development of HPV infections were also investigated. Methods: Patients with a diagnosis of several HPV-induced pathologies including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN), cervical and anal-colorectal cancer, head and neck squamous cell carcinoma (HNSCC) and anogenital warts (AWs) were evaluated. Utilities, quality of life, and risk factors were elicited using a standardized and computer-guided administration of time trade-off, European Quality of Life 5 Dimensions (EQ-5D), 3 levels, and risk factor questionnaires. Utilities were measured at 6 clinical research centers across Italy. A group of healthy subjects was used as a control. A mean number of 20 healthy subjects was used as a control for each pathology group. Findings: Overall, 600 respondents were eligible for analysis: 465 patients (mean [SD] age, 44.0 [16.3] years) and 135 controls (mean [SD] age, 44.0 [13.2] years). With the exception of anal and HNSCC cancer, no statistically significant differences were observed between case and control groups, in terms of either age or quality of life at the time of interview. The patients' perception of their health condition at baseline was equal to an EQ-5D score of 0.87 (0.22). The mean (SD) value of utilities associated with the HPV-induced pathologies corresponded to 0.83 (0.24), 0.78 (0.27), 0.83 (0.22), 0.81 (0.27), 0.58 (0.31), 0.51 (0.26), and 0.69 (0.30) for ASC-US, AWs, CIN 1 (mild), CIN 2-3 (moderate to severe), cervical cancer, anal cancer and HNSCC, respectively. Utility lost due to AWs was significantly higher in females compared with males (0.71 [0.29] vs 0.83 [0.25]; P = 0.018). Having >5 sexual partners increased the risk of acquiring HPV-induced infections as much as 2.52-fold (P = 0.004), whereas for smoking or the age at start of sexual activity younger than 18 years, the risk increased by ∼ 1.62-fold (P = 0.034). High levels of education were associated with a statistically significant protective effect (P <0.001). Implications: Risk factors and utilities elicited in this study can be used as part of future economic assessments of other HPV vaccination strategies, including an immunization program for preadolescents of both sexes in Italy.

KW - Anal cancer

KW - Anogenital warts

KW - Cervical cancer

KW - CIN 1

KW - CIN 2-3

KW - Head and neck squamous cell carcinoma

KW - HPV

KW - Quality of life

KW - TTO

KW - Utilities

UR - http://www.scopus.com/inward/record.url?scp=84920792456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920792456&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2014.11.002

DO - 10.1016/j.clinthera.2014.11.002

M3 - Article

VL - 37

SP - 156

EP - 167

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -